^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | carboplatin (Tubulin polymerization promoter) + docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Published date:
03/29/2021
Excerpt:
The 3 PDX models derived from patients with gBRCA-1 or gPALB2 mutations were very sensitive to carboplatin single agent...The combination of docetaxel and carboplatin was more effective than the drugs used as single agents, except in the PDX from patients with gBRCA1/PALB2 mutations.
DOI:
10.1038/s41598-021-85962-4
